Tokyo, April 17, 2018 – Hitachi Power Solutions Co. Ltd., (“Hitachi Power Solutions”) a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501, “Hitachi”), today announced that it applies Structure Identifier Management Technology (SIMT*1) developed by Hitachi. “Knowledge Base*2 Analytic Solution for Prescriptive Maintenance” strengthens highly developed and speed-up operations on assets and equipment maintenance and it will be launched in Japan and worldwide in May, 2018.
Press Releases all
Tokyo, April 11, 2018 --- Hitachi, Ltd. (TSE: 6501, “Hitachi”) today announced that, pursuant to the decision made by President in accordance with the authority delegated by the resolution of the Board of Directors, Hitachi decided to issue stock acquisition rights to Executive Officers and Corporate Officers, as compensation for Fiscal Year 2018, as stock options as stock-based compensation regarding the grant of stock options announced on March 28, 2018.
The following is a description of the stock acquisition rights to be issued.
Tokyo, April 4, 2018 --- Hitachi, Ltd. (TSE:6501, “Hitachi”) announced today that it has received an order for a heavy ion therapy system from the Taipei Veterans General Hospital (Deh-Ming Chang, MD, PhD; Superintendent) in Taiwan. The order marks Hitachi’s first heavy ion therapy project outside of Japan.
Tokyo, April 3, 2018 --- Hitachi, Ltd. (TSE:6501, “Hitachi”) and UMC Electronics Co ., Ltd. (TSE:6615 “UMC Electronics”) today announced that the companies reached a basic agreement on collaboration for strengthening manufacturing in the IT product field, including server, storage, network equipment. Under this agreement, UMC Electronics will acquire stocks of Hitachi Information & Telecommunication Manufacturing, Ltd. (“HITM”) , a wholly owned subsidiary of Hitachi, as well as the manufacturing assets of the related manufacturing bases owned by Hitachi.
LONDON / ZAANDAM / TOKYO; March 29, 2018 – Hitachi Europe Ltd., Mitsubishi Motors and ENGIE have demonstrated a pioneering project to explore the potential for electric vehicles to act as a means of energy storage for an office building. For this demonstration, the consortium linked the first vehicle to everything (V2X) charger to ENGIE’s office building in Zaandam.
Tokyo, March 28, 2018 --- Hitachi, Ltd. (TSE: 6501, “Hitachi”) resolved to grant stock options as stock-based compensation (stock acquisition rights), with stock price conditions, to Executive Officers as compensation for Fiscal Year 2018 at the meeting of the Compensation Committee held today. Furthermore, Hitachi will grant similar stock options as stock-based compensation (stock acquisition rights) to Corporate Officers, the executive positions next to Executive Officers.
Tokyo, March 28, 2018 – Hitachi, Ltd. (TSE:6501) today announced director candidates to be proposed at its annual general meeting of shareholders in June 2018, in accordance with a resolution at a meeting of Nominating Committee convened today.
Tokyo, Japan, March 22, 2018 --- Hitachi, Ltd. (TSE:6501, “Hitachi”) announced today that it has agreed to invest in a fund managed by Geodesic Capital, a venture capital company active mainly in Silicon Valley. By investing in this fund, Hitachi will help to accelerate open innovation with startup companies in Silicon Valley using Geodesic Capital’s extensive network.
Naples (Italy), 13th March 2018 --- Hitachi Rail Italy today announced that it has signed a contract with Metroselskabet, a partnership of the municipality of Copenhagen, the Danish Government and the city of Frederiksberg, for the supply of eight driverless trains for the M1/M2 lines of the Copenhagen Metro. The contract was signed on 7th March and has a value of approximately EUR 50 million.
Tokyo, March 12, 2018 --- Hitachi, Ltd. (TSE: 6501, Hitachi) and University of Utah Health (U of U Health), a leading institution in electronic health records and interoperable clinical information systems research, today announced the joint development of a decision support system that allows clinicians and patients to choose from available pharmaceutical options for treating type-2 diabetes mellitus (T2DM).